+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 352 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are studying lung mechanics during the early phase of mechanical ventilation in intensive care and during general anesthesia in surgical patients. The study aims to better understand lung compliance and transpulmonary driving pressures using a new, non-invasive PEEP-step method. This method could improve how ventilator settings are personalized to reduce lung injury and complications, addressing a gap in data collected during the critical first hours of ventilation. The study observes two groups ICU patients receiving ventilator treatment and patients undergoing general anesthesia for surgery. In both groups, a PEEP-step method involves adjusting positive end-expiratory pressure PEEP up and down in one or two steps while measuring changes in lung volume and pressures. This is done directly after intubation and repeated during ventilation or surgery when clinical events occur, using specialized software that analyzes data from standard ventilator monitoring equipment. Participants will be monitored continuously during ventilator treatment or surgery. Measurements include lung elastance and transpulmonary driving pressure, collected before, during, and after respiratory care. Clinical data such as blood gases and ventilator settings are recorded without any invasive procedures. The study assesses lung function changes over time, ventilator duration, and postoperative complications, aiming to enhance ventilator therapy and patient outcomes. Total participation time varies with clinical course.

Age: 18Years +All Genders
1 location
F

Actively Recruiting

Researchers are evaluating Flexilev, a Parkinsons disease medicine made of small dissolvable tablets containing low doses of levodopa and carbidopa. The study focuses on how well patients accept and stick with this treatment when delivered using the OraFID dosing device, which accurately dispenses the right number of tablets, and the optional Levilog app that reminds patients to take their doses and records usage. This is an open-label, phase 4 study involving patients with idiopathic Parkinsons disease that responds to levodopa. Participants first undergo a run-in period of up to two weeks where their current treatment is recorded and eligibility is assessed. Eligible patients then switch to Flexilev delivered via the OraFID device and receive individualized dosing based on their doctors evaluation. Other daytime levodopa medications are stopped, though slow-release levodopa at night is allowed. After starting treatment, patients receive follow-up phone calls at weeks 1, 4, and 8, and an in-person visit at week 12, with dose adjustments allowed as needed during the 12-week treatment period. During the study, participants acceptability and satisfaction with the OraFID device and the Levilog app are assessed through questionnaires. Researchers also monitor treatment compliance, safety, changes in motor and non-motor symptoms, depression, quality of life, sleep quality, and disease severity. The total participation lasts up to 12 weeks after the run-in period, with regular phone and in-person assessments to track treatment experience and effects.

Age: 30Years +All GendersPhase 4
5 locations
S

Actively Recruiting

Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.

Age: 18Years +All GendersPhase 2
72 locations
O

Actively Recruiting

Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.

Age: 18Years +All GendersPhase 1Phase 2
114 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and distribution of a drug called 177LuLu-ABY-271 in people with HER2-positive metastatic breast cancer. This early phase 1 trial aims to understand how the drug behaves in tumors and key organs, helping to guide future treatments. The study is open-label and randomized, involving female participants aged 18 and older with advanced breast cancer confirmed by specific tests. The trial has two parts. Part A will enroll up to 6 participants to study how the drug is absorbed by tumors and critical organs after a single infusion. Part B will include 15 participants divided into three groups, each receiving a different protein mass dose with varying radioactivity levels, to determine the best dose for future studies. Treatments are given as a single infusion of 177LuLu-ABY-271. Participants will be closely monitored through assessments of side effects and dose-limiting toxicities up to 29 days for Part A and 43 days for Part B. Researchers will also measure radiation absorbed by organs and tumors within 8 days after treatment. The study includes regular evaluations of tumor size, health status, and overall safety. The total participation time varies depending on the study part and dosing schedule.

Age: 18Years +FEMALEPhase 1
3 locations
G

Actively Recruiting

Researchers are investigating new medicines for children and young people up to 25 years old with relapsed or refractory B-cell non-Hodgkin Lymphoma B-NHL, a type of cancer affecting lymph nodes and organs like the liver or spleen. This international adaptive trial aims to find safer and more effective treatments, focusing on three groups receiving different novel therapies. The study uses a design that allows adding or removing treatments based on their effectiveness and safety in this rare cancer. Participants will receive one of three treatments odronextamab given by intravenous infusion weekly and then less frequently over up to two years loncastuximab tesirine combined with modified R-ICE chemotherapy for up to three cycles or CAR T-cell therapy with details to be confirmed. These treatments are tested in parallel groups, and if a medicine appears ineffective, it may be stopped and replaced by another. The trial allows children to switch groups if their cancer does not respond. During the study, researchers will monitor participants through regular assessments including imaging and laboratory tests to evaluate cancer response and side effects. They will check treatment responses at specific times during treatment cycles and follow patients for at least two years after treatment to monitor long-term outcomes and safety. This includes tracking survival times, adverse events, and overall treatment effectiveness to provide important information about these new therapies.

Age: 0 - 25YearsAll GendersPhase 2Phase 3
11 locations
P

Actively Recruiting

Researchers are investigating ways to personalize treatment for patients with head and neck squamous cell carcinoma HNSCC, especially those with advanced disease who face a higher risk of treatment failure. This phase III study compares two radiotherapy approaches for patients intended for curative treatment the standard radiotherapy and a hyperfractionated radiotherapy HFX-RT with a higher total radiation dose. The study also aims to improve prognostic and predictive methods by including exploratory analyses such as MRI to evaluate tumor hypoxia, gene profiling, immune profiling, and imaging texture analyses during treatment and follow-up. Participants will be randomly assigned to either standard radiotherapy, which delivers 68.0 Gy in daily fractions of 2.0 Gy, or to hyperfractionated radiotherapy, which delivers 83.0 Gy in smaller doses twice daily 1.22 Gy per fraction over five days per week. The doses vary depending on the tumor volume and lymph node involvement. Patients with lower-risk tumors not eligible for randomization may still participate in the translational research parts of the study. During the study, participants will be closely monitored with regular follow-up visits every three months for two years, then every six months up to five years, focusing on local tumor control. Researchers will collect imaging data, conduct gene and protein analyses, and assess tumor response. The study evaluates treatment effects and tumor behavior over time to better understand and improve outcomes for head and neck cancer patients.

Age: 18Years - 100YearsAll GendersPhase 3
11 locations
W

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a behavioural intervention called Light, activity and sleep in my daily life LAS aimed at improving quality of life for community-dwelling older adults aged 70 and over. The study focuses on addressing challenges related to circadian rhythm sleep disorders, poor sleep, reduced physical activity, and time spent indoors, which affect wellbeing in this population. The intervention targets light-related behaviour, outdoor walking, and sleep routines to promote active ageing and independence. The LAS intervention is delivered as a 9-week web-based course with nine modules covering electric lighting, daylight, outdoor physical activity, and sleep. Participants also receive a test kit with items like light bulbs, a sleep mask, and a sleep diary to support engagement and experimentation. The course includes one introductory physical meeting and three additional meetings held at a senior citizen meeting point. All participants receive the same noninvasive behavioural education and support. Participants complete questionnaires, interviews, and wear accelerometers to track activity and rest patterns before and after the course, with follow-ups at 3, 6, and 10 months after baseline. Outcomes measured include usability of the intervention, mood, sleep quality, behavioural skills, quality of life, physical activity, sedentary behaviour, and step counts. The study also explores factors that help or hinder daytime outdoor walking. Results will guide improvements for future delivery within municipal health promotion services.

Age: 70Years +All GendersPhase Not Applicable
4 locations
E

Actively Recruiting

Researchers are evaluating a new rehabilitation process to assess and relieve chemotherapy-induced peripheral neuropathy in the feet of patients treated for early-stage breast cancer. This study compares two orthopedic supports a standard treatment using customized insoles and shoes, and a novel silicone orthosis designed as a soft, sock-like device for indoor use. The goal is to understand if the silicone orthosis can reduce symptoms and improve function compared to standard treatment. Participants will be randomly assigned to receive either the customized insoles and shoes or the silicone orthosis along with the standard treatment. The study involves initial assessments including symptom grading, foot health questionnaires, quality of life scales, and 3D foot scanning. Activity levels will be tracked using an activity sensor worn on the leg for two weeks. Participants using the silicone orthosis will keep a diary of device usage. Follow-ups occur 3 to 6 weeks after starting the intervention to evaluate symptom changes and patient experiences. During the study, participants will undergo foot examinations and complete questionnaires about their symptoms, foot health, and quality of life. Mobility and activity patterns will be monitored objectively with activity trackers. Follow-up may be conducted in person, by phone, or digitally, lasting about 45 minutes. The main outcomes include changes in neuropathy symptoms and physical activity after 3 to 6 weeks of using the orthopedic devices. This research aims to improve rehabilitation care for breast cancer survivors experiencing foot neuropathy from chemotherapy.

Age: 18Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of chemotherapy treatments in adults diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN. This observational study aims to provide comparative data to the ELZONRIS registry study by reviewing real-world outcomes of patients treated with various chemotherapy regimens as their first-line therapy since May 2016. Participants have received chemotherapy regimens similar to those used for acute myeloid leukemia, acute lymphocytic leukemia, or lymphoma, with choices made by their healthcare providers based on institutional practices. No study medication is provided by the sponsor. The study collects data retrospectively without administering new treatments. During the study, researchers collect information on response rates, duration of response, progression-free and overall survival, adverse events, transfusion needs, treatment durations, hospitalization details, and transitions to stem cell transplant. Data is gathered from the start of treatment through up to 26 months, offering insights into treatment patterns and outcomes. Participants privacy and consent are managed following local regulations.

Age: 18Years +All Genders
67 locations

1-10 of 352

1